Connective Tissue Growth Factor (CTGF/CCN2) is a critical matricellular protein that coordinates extracellular matrix (ECM) remodeling, tissue fibrogenesis, and tumor-stroma interactions. As a major downstream mediator of TGF-beta signaling, CTGF has emerged as a high-value therapeutic target for idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and desmoplastic tumors. Developing highly selective therapeutics against CTGF requires rigorous domain-specific validation and off-target screening within the CCN family.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CTGF drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CTGF ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CTGF Products |
| Gene Delivery | CTGF Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based assays. |
View CTGF Products |
| Benchmark Ab | Anti-CTGF (Sequence of Pamrevlumab) Recombinant positive control antibody for binding and functional assays. |
View CTGF Products |
| Validator | CTGF siRNA Set For knockdown verification and functional specificity validation. |
View CTGF Products |
| Related Target A | TGFB1 Primary upstream driver of CTGF expression; essential for synergistic pathway inhibition assays. |
View TGFB1 Products |
| Related Target B | ITGAV Integrin alpha-V; interacts with CTGF to mediate cell adhesion and fibrotic signaling. |
View ITGAV Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Domain-specific epitope mapping | Domain-specific truncated recombinant proteins (Domains 1-4) available with >95% purity. |
| CCN family cross-reactivity screening | Homolog panel proteins (CCN1/CYR61, CCN3/NOV) strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Pamrevlumab biosimilar) included for assay standardization. |
| False Positives in ECM Binding | Sequence-verified siRNA sets included for target knockdown and specificity validation. |
Live CTGF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The clinical development of CTGF-targeted therapeutics has been pioneered by monoclonal antibodies, most notably Pamrevlumab. While first-generation clinical trials in idiopathic pulmonary fibrosis (IPF) and Duchenne muscular dystrophy (DMD) have highlighted the complexity of fibrotic disease biology, the therapeutic rationale for CTGF inhibition remains robust. The next wave of R&D is shifting toward combination regimens (e.g., co-targeting CTGF and TGF-beta pathways) and multi-specific modalities designed to localize target engagement within highly fibrotic or desmoplastic microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | FibroGen | IPF, Pancreatic Cancer, DMD | Domain-specific binding affinity (Need high-purity HEK293-expressed CTGF) |
| RNA Interference (siRNA/ASO) | RXi Pharmaceuticals, Alnylam | Hypertrophic Scarring, Fibrosis | In vitro knockdown verification (Need validated siRNA and Lentivirus for stable lines) |
| Bispecific / Fusion Proteins | Biotech Innovators | Solid Tumors, Severe Fibrosis | Dual-target binding kinetics (Need high-purity CTGF and TGFB1 recombinant proteins) |